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To the Editor—We have read with 
great interest the article by Foolad et  al 
[1] reporting on the use of oral versus in-
haled ribavirin (RBV) to treat respiratory 
syncytial virus infection in hematopoietic 
cell transplant recipients in their center. 
They concluded that oral RBV may be an 
effective alternative to aerosolized RBV. 
Although their results are surely prom-
ising in light of significant cost savings 
and availability of treatment, a few ques-
tions remain to be answered. As the au-
thors stated, neither the optimal dosing 
regimen nor the optimal treatment dura-
tion of RBV are established yet. 
Our group published in 2018 the results 
of a population pharmacokinetic model 
analyzing current and proposed dosing 
regimens for RBV in lung transplant re-
cipients [2]. This model examined several 
dosing strategies using either oral or in-
travenous loading doses of RBV, followed 
by oral maintenance dosing. Simulation of 
a regimen similar to that used by Foolad 
et  al (11  mg/kg every 8 hours, followed 
by 10 mg/kg every 12 hours) resulted in 
quick attainment of target concentrations 
(2.5–3.0 mg/L) but may result in escala-
tion of concentrations over the 14-day 
treatment period, possibly causing se-
rious side effects including development 
of anemia. Although Foolad et al [1] re-
ported treatment for a median of only 
5 days, they found new-onset anemia in 
no orally treated patients at day 7, but in 
6.9% of them at day 14. Although there 
is interindividual variation in the devel-
opment of anemia, owing to variations in 
several host factors [3], hemoglobin may 
start to fall, with RBV plasma concen-
trations >3.5 mg/L [4, 5]. Proposed oral 
treatment regimens found by our model, 
comprising loading doses of either 11 mg/
kg every 8 hours for the first 24 hours or 
8  mg/kg every 6 hours for the first 48 
hours, followed by a maintenance dose of 
4 mg/kg every 12 hours or 8 mg/kg every 
24 hours, may quickly attain target con-
centrations while preventing an overly 
high RBV concentration and therefore 
reducing the likelihood of anemia.
Furthermore as Jain et  al [6] stated in 
their letter, only 18 patients were classi-
fied as high risk, leading to a possibly un-
derpowered comparison of the treatment 
regimens in this important subgroup, and 
it is unclear whether RBV is of benefit in 
mild infections. We analyzed 96 respira-
tory syncytial virus, parainfluenza, and 
human metapneumovirus infections in 
lung transplant recipients in our center and 
found that patients with a severe infection, 
characterized by a >10% drop in forced ex-
piratory volume in 1 second (FEV1) at pre-
sentation, had a lower FEV1 6 months after 
infection than patients with a <10% drop 
at presentation. Furthermore, patients with 
a severe infection who were treated with 
RBV had a higher FEV1 6 months after in-
fection than those who received no RBV, 
but this difference was not present in pa-
tients with mild infection [7]. We recognize 
the importance of the study performed by 
Foolad et al [1] and support the use of oral 
RBV in lung transplant recipients, but we 
also emphasize both the importance of 
considering disease severity in making 
treatment decisions and evaluating effec-
tiveness and the need for pharmacokinetic-
pharmacodynamic research to develop 
optimal treatment regimens.
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Measles, Vaccines, and Types 
of Perception Bias in Public 
Debates
To the Editor—Sparked by the resur-
gence of measles outbreaks, it has become 
increasingly common in popular media 
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advantages and potential risks of vaccines 
[1–5]. It is a frequently used argument 
by antivaccine campaigners that, before 
the 1960s, the decade during which the 
measles vaccine became available, eve-
rybody used to experience these back-
then childhood diseases [6], an argument 
played out to create a connotation of nor-
mality and harmlessness concerning an 
antivaccination choice [1, 3].
However, such an argument contains 
bias. It is known that bias occurs if com-
parisons are made between groups that 
are systematically different with regards 
to certain characteristics [7]. For ex-
ample, the act of remembering a specific 
event may be differential between those 
who had a disease (or an unfavorable 
clinical course of the disease) and those 
without the disease (or a mild course of 
the disease). Although those with unfa-
vorable clinical courses of measles may 
be largely in favor of vaccinations, those 
with mild clinical courses may poten-
tially be opposing it. This is an example of 
reporting bias [7]. However, as the bulk 
of measles-attributable population mor-
bidity and mortality in high-income set-
tings occurred before 1970, it is likely that 
today former patients may not correctly 
remember the severity of their individual 
episodes of measles, thus, constituting a 
form of recall bias [6].
Further, survivorship bias may play a 
role. It denotes the distorted perception of 
an exposure (eg, measles episode) when 
looking only at those with a favorable out-
come (eg, survival). Explicit examples are 
numerous, such as the presumable ease to 
earn public reputation or fame: for every 
successful individual (in art, science, pol-
itics, etc.), there are, however, potentially 
hundreds having engaged in the same 
effort, not having succeeded and thus 
being lost to the formation of the public 
perception process [7, 8]. Similarly, in 
measles vaccination debates, the public 
opinion is virtually exclusively shaped by 
those who survived their measles episode 
in the pre-1970s or had benefitted from 
vaccination campaigns in the post-1970s. 
Contrarily, people with a fatal outcome in 
their measles episode cannot contribute 
to the public debate anymore to advocate 
a provaccination choice.
A similar subtype of bias is the 
so-called visibility bias [9]. It refers to an 
increased awareness for an exposure (eg, 
measles) if its outcome is particularly 
salient or severe (eg, death). Despite a 
rising measles incidence, the average 
case-fatality rate of measles is 1:1000 
and may still be too low in high-income 
settings to surpass the public perception 
threshold [6, 10]. Thus, the absence of 
public “visibility” of severe clinical out-
comes may also be linked to decreased 
willingness to vaccinate.
Finally, one may even regard the com-
position of speakers in public debates to be 
subjected to selection bias. There is broad 
consensus among medical experts that 
the measles vaccine is highly efficacious, 
tolerable, and safe [6, 10]. Thus, a debate 
hosting the same number of favorers as 
there are opposers, conveys (whether 
willingly or unwillingly) a dispropor-
tionate medical reality to the audience 
and an overrepresentation of antivaccine 
campaigners.
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Antibiotic Use in Total Knee 
Arthroplasty Periprosthetic 
Joint Infection
To the Editor—We have read with 
much interest the article by Shah et  al 
[1], describing a 29% higher treatment 
success rate when patients are given an 
extended course of antibiotics compared 
with a 6-week treatment course for knee 
periprosthetic joint infections (PJIs) 
treated with surgical debridement (de-
bridement, antibiotic therapy, and implant 
retention [DAIR]).The authors concluded 
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